Abstracts tagged "prognostic factors"

Abstract Number: 1554 • ACR Convergence 2023
Therapeutic Approaches and Predictive Factors of Relapse in Severe Ocular Involvement in Behçet’s Disease: A Multicentre Retrospective Study
Audrey Hermant¹, Yann Nguyen², Fleur Cohen³, Antoine Baudet⁴, Alban DEROUX⁵, Vincent Poindron⁶, Cécile-Audrey Durel⁷, Nicolas Girszyn⁸, Noémie Le Gouellec⁹, Benedicte Rouviere¹⁰, Helder Gil¹¹, Francois Maurier¹², Nicolas Noel¹³, Loic Raffray¹⁴, Hubert De Boysson¹⁵, Benoit Faucher¹⁶, Bertrand Godeau¹⁷, Pierre Lozach¹⁸, Claude Bachmeyer¹⁹, Alice Berezne⁴, Gilles Blaison²⁰, Brice Castel²¹, Guillaume Gondran²², Matthieu Groh²³, Stéphane Giorgiutti²⁴, Jeremy Keraen²⁵, Julie Magnant²⁶, Sebastien Monnier²⁷, Philippe Blanche²⁸, Dominique Monnet²⁹, Antoine Brezin²⁹ and Benjamin Terrier³⁰, ¹Hopital Cochin, Paris, France, ²Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ³Sorbonne Université, Paris, France, ⁴CH Annecy, Annecy, France, ⁵CHU de Grenoble, Grenoble, France, ⁶Strasbourg, Strasbourg, France, ⁷CHU Lyon, Lyon, France, ⁸Rouen, Rouen, France, ⁹CH Valenciennes, Valenciennes, France, ¹⁰CHU Brest, Brest, France, ¹¹CHU Besancon, Besançon, France, ¹²CH Metz, Metz, France, ¹³CHU Bicetre, Le Kremlin-Bicêtre, France, ¹⁴CHU la Réunion, La Réunion, France, ¹⁵CHU Caen, Caen, France, ¹⁶CHU Marseille, Marseille, France, ¹⁷CHU Henri Mondor, Créteil, France, ¹⁸CH Le Mans, Le Mans, France, ¹⁹CHU Tenon, Paris, France, ²⁰Hôpital Louis PASTEUR, Colmar, France, ²¹CH Tarbes, Tarbes, France, ²²CHU Limoges, Limoges, France, ²³National Referral Center for Hypereosinophilic Syndrome (CEREO), Hôpital Foch, Suresnes, France, ²⁴CHRU Strasbourg, Strasbourg, France, ²⁵CH Quimper, Quimper, France, ²⁶CHU Tours, Tours, France, ²⁷CH Versailles, Versailles, France, ²⁸Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²⁹CHU Cochin, Paris, France, ³⁰Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: The management of severe ocular involvement in Behçet's disease (BD) is an important issue with major functional implications due to the risk of blindness.…
Abstract Number: 2510 • ACR Convergence 2023
Autoantibody-positivity Before Treatment Is Associated with Immune-related Adverse Events in Melanoma Patients Treated with anti-PD-1
Tineke van Wesemael¹, Jessica Borgers², Kyra Gelderman³, Els Verdegaal⁴, C.M. Korse⁵, M.J.P. Welters⁶, Ellen Kapiteijn⁷, W.J. van Houdt², Sjoerd van der Burg⁶, René Toes¹, J.V. Thienen², John Haanen² and Diane van der Woude¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands, ³Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁴Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Amsterdam, Netherlands, ⁵Department of Laboratory Medicine, Antoni Van Leeuwenhoek, The Netherlands Cancer Institute, Amsterdam, Netherlands, ⁶Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Netherlands, ⁷Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: PD-1 immune checkpoint inhibitors are able to re-activate restrained anti-tumor T-cell responses in melanoma patients. However, PD-1 inhibition may also activate auto-reactive T-cells leading…
Abstract Number: 0300 • ACR Convergence 2023
Nailfold Videocapillaroscopy in Idiopathic Inflammatory Myopathy Compared with Healthy Controls
Megan Sullivan¹, Maximiliano Diaz-Menindez², Colleen T. Ball², Benjamin Wang³ and Florentina Berianu¹, ¹Mayo Clinic Florida, Jacksonville, FL, ²Mayo Clinic Jacksonville, Jacksonville, FL, ³Mayo Clinic, Jacksonville, FL
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a group of autoimmune disorders that cause inflammation of the muscle. This includes dermatomyositis and polymyositis. Literature has been…
Abstract Number: 1142 • ACR Convergence 2023
A Retrospective Analysis of Radiographic and Serologic Findings in Patients with Scleroderma and Interstitial Lung Disease
Nikita Jhawar, Claire Wilson, Andy Abril, Li Zhuo and Yaohua Ma, Mayo Clinic, Jacksonville, FL
Background/Purpose: Connective tissue diseases such as scleroderma are frequently associated with interstitial lung disease (ILD). Detection of autoantibodies is crucial in characterizing disease phenotypes, but…
Abstract Number: 1570 • ACR Convergence 2023
Prognostic Assessment of the 2022 ACR/EULAR Classification Criteria for Takayasu Arteritis: A Multi-centre International Study
Emma Rinaldi¹, Corrado Campochiaro², Roberto Padoan³, Chengappa Kavadichanda⁴, Augustine Jose⁴, Kritika Singh⁵, Luca Iorio³, Naomi Viapiana⁶, Upendra Rathore⁵, Elena Marina Baldissera⁶, Vikas Agarwal⁵, Lorenzo Dagna⁷, Durga P Misra⁵ and Alessandro Tomelleri⁸, ¹Vita-Salute San Raffaele University, Milan, Italy, ²IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ³Department of Medicine DIMED, University of Padova, Padova, Italy, ⁴Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ⁶IRCCS San Raffaele Hospital, Milan, Italy, ⁷Ospedale San Raffaele, Milano, Italy, ⁸Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy
Background/Purpose: The 2022 ACR/EULAR classification criteria for Takayasu arteritis (TAK) rely on a point-based clinical and imaging scoring system (from 0 to 22). The aim…
Abstract Number: 2552 • ACR Convergence 2023
Inflammatory Fibrosis Precedes Loss of Kidney Function in Lupus Nephritis
Silvia Malvica¹, Paride Fenaroli², Serena Bagnasco¹, Jeff Hodgin³, Peter Izmirly⁴, H Michael Belmont⁵, Katie Preisinger⁴, Jill Buyon⁶, Larry Magder⁷, Michelle Petri⁸, the Accelerating Medicines Partnership in RA/SLE⁹, Avi Rosenberg¹ and Andrea Fava¹⁰, ¹Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, ²Nephrology and Dialysis Unit, Azienda USL - IRCCS Reggio Emilia, Reggio Emilia, Italy, ³University of Michigan, Ann Arbor, MI, ⁴New York University School of Medicine, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁷University of Maryland, Baltimore, MD, ⁸Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁹Multiple, Multiple, ¹⁰Johns Hopkins University, Baltimore, MD
Background/Purpose: Interstitial fibrosis in lupus nephritis (LN) is often infiltrated by immune cells. However, this is typically regarded as nonspecific "scar reaction" rather than active…
Abstract Number: 0320 • ACR Convergence 2023
Feasibility and Acceptability of Geniculate Artery Embolization for the Treatment of Painful Knee Osteoarthritis
Amaya Smole¹, Benjamin Swett¹, Alison Zhao¹, Yvonne Shea¹, Sarah Gottesman¹, Dongmei Sun¹, Geoffrey Westrich¹, Michael Alexiades¹, Alejandro Gonzalez Della Valle¹, Sirish Kishore² and Lisa Mandl³, ¹Hospital for Special Surgery, New York, NY, ²Stanford Medicine, Stanford, CA, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: There are limited non-surgical options for patients with severe pain due to knee osteoarthritis (KOA).Using geniculate artery embolization (GAE) to infarct hypervascular synovium, a…
Abstract Number: 1160 • ACR Convergence 2023
Antibody Predictors of Prognosis in a Large Multi-centre Cohort of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease
Jennifer Hannah¹, Alexandra Lawrence², Jennifer Martinovic², Marium Naqvi², Saadia Sasha Ali³, Carmel Stock⁴, Cara Owens⁴, Anand Devaraj⁴, Louise Pollard², Sangita Agarwal², Belén Atienza-Mateo⁵, Amit Patel⁶, Alex West², Kate Tinsley², Hasti Robbie⁷, Felix Chua⁴, Boris Lams², Athol Wells⁴, Sam Norton⁷, James Galloway⁷, Elisabetta Renzoni⁴ and Patrick Gordon⁸, ¹King's College London, London, United Kingdom, ²Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ³King's College Hospital, Epsom, United Kingdom, ⁴Royal Brompton and Harefield Hospitals NHS Trust, London, United Kingdom, ⁵Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶King's College Hospital, London, United Kingdom, ⁷King's College London, London, United Kingdom, ⁸NHS, London, United Kingdom
Background/Purpose: IIM-ILD follows a varied clinical course. Serological profile can help predict clinical phenotype, but impact on ILD prognosis is less clear. This multicentre UK…
Abstract Number: 1699 • ACR Convergence 2023
Immunosuppression with Targeted Therapies Reduces Morbidity and Mortality in Pre-Capillary Pulmonary Hypertension Associated with Systemic Sclerosis: A EUSTAR Analysis
Cosimo Bruni¹, Havard Fretheim², Lorenzo Tofani³, Yannick Weber¹, Eric Hachulla⁴, Patricia Carreira⁵, Dilia Giuggioli⁶, Paolo Airò⁷, Elise Siegert⁸, Ulf Müller-Ladner⁹, marco Matucci Cerinic¹⁰, Gabriela Riemekasten¹¹, Carmen Pilar Simeon-Aznar¹², Jeska de Vries-Bouwstra¹³, Lesley Ann Saketkoo¹⁴, Joerg Distler¹⁵, Alexandra Balbir-Gurman¹⁶, Ivan Castellvi¹⁷, Elisabetta Zanatta¹⁸, Vanessa Smith¹⁹, Christopher Denton²⁰, Britta Maurer²¹, Alessandro Giollo¹⁸, Florenzo Iannone²², Lorenzo Dagna²³, Marie-Elise Truchetet²⁴, Masataka Kuwana²⁵, Yannick ALLANORE²⁶, Yoshiya Tanaka²⁷, Mickael Martin²⁸, Edoardo Rosato²⁹, Ana Maria Gheorghiu³⁰, Francesco Del Galdo³¹, Kamal Solanki³², Alessandra Vacca³³, CATARINA RESENDE³⁴, SUSANA VIEIRA³⁵, Laszlo Czirjak³⁶, Marko Barisic³⁷, Francesco Paolo Cantatore³⁸, valeria Riccieri³⁹, Kristofer Andréasson⁴⁰, Lorinda Chung⁴¹, Carolina Muller⁴², Daniela OPRIS-BELINSKI⁴³, Simona Rednic⁴⁴, Petros Sfikakis⁴⁵, Yair Levy⁴⁶, Anna Maria Hoffmann-Vold⁴⁷, Oliver Distler¹, Vivien Hsu⁴⁸, Stefan Heitmann⁴⁹, Gianluca Moroncini⁵⁰, Michele Iudici⁵¹, Joerg Henes⁵², Ellen De Langhe⁵³, Ariane Herrick⁵⁴ and Carlomaurizio Montecucco⁵⁵, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Oslo University Hospital, Oslo, Norway, ³Department of Statistics, Computer Science, Applications, University of Florence, Florence, Italy, ⁴University of Lille, Lille, France, ⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, ⁷Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, ⁸Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, ⁹Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, ¹⁰Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹¹University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ¹²Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitario Vall d'Hebronh, Barcelona, Spain, ¹³Leiden University Medical Center, Leiden, Netherlands, ¹⁴University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, ¹⁵Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ¹⁶Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ¹⁷Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ¹⁸Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy, ¹⁹Ghent University Hospital, Gent, Belgium, ²⁰University College London, London, United Kingdom, ²¹University Hospital Bern, University Bern, Bern, Switzerland, ²²Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ²³Ospedale San Raffaele, Milano, Italy, ²⁴Bordeaux University Hospital, Bordeaux, France, ²⁵Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²⁶Université Paris Cité, Paris, France, ²⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁸Department of Internal Medicine, INSERM U1313, Poitiers University, Poitiers University Hospital, Poitiers, France, ²⁹Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy, ³⁰Department of Internal Medicine and Rheumatology, Ion Cantacuzino Clinical Hospital, Bucharest, Romania, ³¹University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ³²Department of Rheumatology, Te Whatu Ora Health New Zealand Waikato, Hamilton, New Zealand, ³³II Chair of Rheumatology, University of Cagliari-Policlinico Universitario, Monserrato, Italy, ³⁴Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Lisboa, Portugal, ³⁵Hospital Fernando Fonseca, Lisbon, Portugal, ³⁶Dept. Rheumatol Immunol, Medical School, university of Pecs, Pecs, Hungary, ³⁷Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia, ³⁸Rheumatology Clinic – Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy, ³⁹Department of Clinical, Internal and Cardiovascular Specialities, Sapienza University of Rome, Roma, Italy, ⁴⁰Lund University, Lund, Sweden, ⁴¹Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, ⁴²Federal University of Parana, CURITIBA / PR, Brazil, ⁴³Saint Mary Hospital, Bucharest, Romania, ⁴⁴Prof Dr Simona Rednic, Cluj, Romania, ⁴⁵National Kapodistrian University of Athens Medical School, Athens, Greece, ⁴⁶Meir Medical Center, Autoimmune Research Laboratory, Kfar-Saba, Israel, ⁴⁷Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ⁴⁸Rutgers-RWJ Medical School, South Plainfield, NJ, ⁴⁹Department of Rheumatology, Marienhospital Stuttgart, Böheimstrasse 37, D-70199, Stuttgart, Germany, ⁵⁰Marche Polytechnic University, Ancona, Italy, ⁵¹Division of Rheumatology, Department of Internal Medicine Specialties, Geneva University Hospitals, Geneva, Switzerland, ⁵²University Hospital Tuebingen, Tuebingen, Germany, ⁵³Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium, ⁵⁴University of Manchester, Salford, United Kingdom, ⁵⁵Unità Operativa e Cattedra di Reumatologia, IRCCS Policlinico S Matteo, Pavia, Italy
Background/Purpose: Systemic sclerosis (SSc) associated pre-capillary pulmonary hypertension (precapPH) is a severe condition that requires prompt treatment. Although immunosuppressants (IMS) are standard of care for…
Abstract Number: 2554 • ACR Convergence 2023
Validation of a Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus in a Confirmatory Cohort
Melissa Munroe¹, Derek Blankenship², Daniele DeFreese², Adrian Holloway², Mohan Purushothaman², Wade DeJager³, Susan Macwana³, Joel Guthridge³, Stan Kamp³, Nancy Redinger³, Teresa Aberle³, Eliza Chakravarty³, Cristina Arriens⁴, Yanfeng Li⁵, Hu Zeng⁵, Stephanie Dezzutti⁶, Peter Izmirly⁷, Uma Thanarajasingam⁵, Diane L. Kamen⁶, Jill Buyon⁸, Judith James³ and Eldon Jupe², ¹Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, ⁵Mayo Clinic, Rochester, MN, ⁶Medical University of South Carolina, Charleston, SC, ⁷New York University School of Medicine, New York, NY, ⁸NYU Grossman School of Medicine, New York, NY
Background/Purpose: SLE is marked by immune dysregulation linked to varied clinical disease activity. Using a unique confirmatory cohort of SLE patients, this study seeks to…
Abstract Number: 0382 • ACR Convergence 2023
Heterogeneity Within a “difficult to Treat” Rheumatoid Arthritis Patients Cohort: 36% May Have a More Benign Course and Have Distinct Characteristics at bDMARD or tsDMARD Initiation
Irini Flouri¹, Antonios Bertsias², Argyro Repa², Nestor Avgoustidis², Eleni Kalogiannaki², Sofia Pitsigavdaki³, George Bertsias⁴ and Prodromos Sidiropoulos⁴, ¹University of Crete Medical School, Heraklion, Greece, ²Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Heraklion, Greece, ³Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece, ⁴Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece
Background/Purpose: Early detection of difficult to treat (D2T) RA patients as well as better characterization of their long-term course represent unresolved issues. Herein we aimed…
Abstract Number: 1167 • ACR Convergence 2023
Transcriptome Analysis of Peripheral Blood Reveals Superiority of the Triple Combination of Baricitinib, Rituximab, and Tacrolimus Therapy (BRT-Tx.) for anti-MDA5 Antibody-positive Dermatomyositis (MDA5-DM)
Yoshinobu Koyama¹, Yoshiharu Sato², Yu Nakai³ and Moe Tokunaga(Sakamoto)³, ¹Japanese Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc, Tokyo, Japan, ³Rheumatology, Center for Autoimmune diseases, Japanese Red Cross Okayama Hospital, Okayama, Japan
Background/Purpose: MDA5-DM is characterized by high mortality due to rapid progressive ILD. We reported that in MDA-5DM, (1) RIG-1-like receptor signaling is enhanced, (2) antiviral…
Abstract Number: 1972 • ACR Convergence 2023
Evaluation of Myositis Autoantibodies as Predictors of Response to IVIG: Post-hoc Analysis of a Large Randomized, Double-Blind, Placebo-Controlled Phase III Trial
Christina Charles-Schoeman¹, Joachim Schessl², Rohit Aggarwal³ and and the ProDERM investigators⁴, ¹UCLA Medical Center, Santa Monica, CA, ²Friedrich-Baur-Institute, Ludwig-Maximilians University of Munich, Munich, Germany, ³University of Pittsburgh, Pittsburgh, PA, ⁴Institutions in Europe and North America, Vienna, Austria
Background/Purpose: Dermatomyositis (DM) is an immune-mediated inflammatory myopathy (IIM). Two subsets ofautoantibodies have been identified in patients with IIM: Myositis-specific antibodies (MSA) and myositis-associated antibodies…
Abstract Number: 2561 • ACR Convergence 2023
The Prognostic Value of the “2022 ACR/EULAR Classification Criteria for Giant Cell Arteritis”: Data from the Italian Society of Rheumatology Vasculitis Study Group
Alessandro Tomelleri¹, Corrado Campochiaro², Francesco Muratore³, Sara Monti⁴, Nicola Farina⁵, Chiara Marvisi⁶, Elena Galli⁷, Alessandra Milanesi⁸, Naomi Viapiana⁵, Alvise Berti⁹, Roberto Bortolotti⁹, Milena Bond¹⁰, Roberto Padoan¹¹, Mara Felicetti⁹, Franco Schiavon¹², Carlotta Nannini¹³, Fabrizio Cantini¹³, Alessandro Giollo¹⁴, Maurizio Rossini¹⁵, Edoardo Conticini¹⁶, Bruno Frediani¹⁷, Fabrizio Conti¹⁸, Roberta Priori¹⁸, Marco Sebastiani¹⁹, Giulia Cassone²⁰, Luca Quartuccio Quartuccio²¹, Elena Treppo²², Silvano Bettio²³, Ariela Hoxha²⁴, Marco Lovisotto²⁴, Giacomo Emmi²⁵, irene mattioli²⁶, Pietro Leccese²⁷, Roberto F. Caporali²⁸, Lorenza Maria Argolini²⁹, Rosario Foti³⁰, Elisa Visalli³⁰, Michele Colaci³¹, Carlomaurizio Montecucco³², Lorenzo Dagna³³ and Carlo Salvarani³⁴, ¹Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ²IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ³IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, ⁵IRCCS San Raffaele Hospital, Milan, Italy, ⁶IRCCS di Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁷Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy, ⁸Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ⁹Santa Chiara Hospital of Trento, Trento, Italy, ¹⁰Azienda sanitaria dell'Alto Adige, Merano, Italy, ¹¹Department of Medicine DIMED, University of Padova, Padova, Italy, ¹²University of Padova, Padova, Italy, ¹³Santo Stefano Hospital Prato, Prato, Italy, ¹⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy, ¹⁵Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy, ¹⁶Tallaght University Hospital, Dublin, Ireland, ¹⁷University of Siena, Siena, Italy, ¹⁸University of Rome La Sapienza, Rome, Italy, ¹⁹Azienda Policlinico di Modena, Modena, Italy, ²⁰University of Modena and Reggio Emilia, Modena, Italy, ²¹Rheumatology Division, Department of Medicine, University of Udine, Udine, Italy, ²²Physician, Moimacco, Italy, ²³University of Padua, Treviso, Italy, ²⁴San Bortolo Hospital of Vicenza, Vicenza, Italy, ²⁵University of Florence, Florence, Italy, ²⁶University of Florence, Firenze, Italy, ²⁷Regional Hospital San Carlo, Potenza, Italy, ²⁸Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, ²⁹ASST Gaetano Pini, Milano, Italy, ³⁰AOU San Marco, Catania, Catania, Italy, Catania, Italy, ³¹University of Catania, Catania, Italy, ³²Unità Operativa e Cattedra di Reumatologia, IRCCS Policlinico S Matteo, Pavia, Italy, ³³Ospedale San Raffaele, Milano, Italy, ³⁴Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: The 2022 classification criteria for giant cell arteritis (GCA) have been recently published. The aim of this study is to investigate whether the score…
Abstract Number: 0392 • ACR Convergence 2023
Novel Diagnostic Markers for Rheumatoid Arthritis Including Anti-CarP (Carbamylated Protein), Anti-Sa (Citrullinated Vimentin) and Anti-CEP1 (Citrullinated Enolase Peptide1) Are Frequently Positive in Diagnostic Profiles
Jane Yang¹, Rubio Punzalan¹, Lehrhoff Andrew¹, Michael Nappi¹, Vincent ricchiuti², Michael Zikry¹ and Kelly Chun¹, ¹Labcorp, Calabasas, CA, ²Labcorp, Dublin, OH
Background/Purpose: Despite the diagnostic contribution of Anti-CCP3.1 (cyclic citrillunated peptide) antibody and RF (rheumatoid factor) as classified by the 2010 ACR/EULAR RA criteria, approximately one-third…

« Previous Page
1
…
7
8
9
10
11
…
21
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].